Revisión de nefropatía diabética

Objetivo: realizar una revisión de la literatura respecto a la nefropatía diabética y exponer las estrategias farmacológicas y no farmacológicas basadas en la evidencia más recientes para prevenir la progresión de la enfermedad renal crónica en los pacientes diabéticos.

Método: se realizó una revisión de la literatura mediante búsqueda bibliográfica en la base de datos PubMed, utilizando cinco términos MeSH que permitieran responder a nuestro objetivo.

Conclusión: la enfermedad renal es una complicación frecuente en los pacientes que padecen diabetes. Hasta el momento no existe una forma específica aplicable a todos los pacientes que permita predecir con precisión quién desarrollará la enfermedad renal terminal. Se conocen algunos factores que precipitan y otros que retardan la progresión de esta entidad, en la actualidad existen varias alternativas terapéuticas para disminuir la progresión del deterioro renal en los pacientes con diabetes.

Jiang G, Luk AOY, Tam CHT, Xie F, Carstensen B, Lau ESH, et al. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes. Kidney Int. 2019 en.;95(1):178-87. doi: 10.1016/j.kint.2018.08.026

Garg D, Naugler C, Bhella V, Yeasmin F. Chronic kidney disease in type 2 diabetes: Does an abnormal urine albumin-to-creatinine ratio need to be retested? Can Fam Physician. 2018;64(10):e446-52.

American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes - 2020. Diabetes Care. 2020 en.;43(supl. 1):S135-51. doi: 10.2337/dc20-S011.

Górriz JL, Soler MJ, Navarro-González JF, García-Carro C, Puchades MJ, D’Marco L, et al. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. J Clin Med. 2020 mzo. 30;9(4):947. doi: 10.3390/jcm9040947.

Ortega EA. Prevalencia y características clínicas de la nefropatía diabética Prevalence and clinical characteristics of diabetic nephropathy. Rev Nac. 2013;5:10.

Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G, et al. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. Nutr Metab Cardiovasc Dis. 2019 nov.;29(11):1127-50. doi: 10.1007/s40620-019-00650-x.

Sulaiman MK. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndr. diciembre de 2019;11(1):7. doi: 10.1186/s13098-019-0403-4

Kornelius E, Lo S-C, Huang C-N, Wang Y-H, Yang Y-S. Association of blood glucose and renal end points in advanced diabetic kidney disease. Diabetes Res Clin Pract. 2020 mzo.;161:108011. doi: 10.1016/j.diabres.2020.108011

Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2020 abr.;8(4):301-12. doi: 10.1016/S2213-8587(20)30026-7

Bae JH, Kim S, Park E-G, Kim SG, Hahn S, Kim NH. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Endocrinol Metab. 2019;34(1):80-92. doi: 10.3803/EnM.2019.34.1.80

Dávila AV. Nefropatía diabética. ARS MEDICA Rev Cienc Médicas. 1999;28(1):42-4.

Tziomalos K, Athyros VG. Diabetic nephropathy: new risk factors and improvements in diagnosis. Rev Diabet Stud. 2015;12(1-2):110-8. doi: 10.1900/RDS.2015.12.110

Wang Y, Chen F, Wang J, Wang T, Zhang J, Han Q, et al. The relationship between increased ratio of visceral-to-subcutaneous fat area and renal outcome in Chinese adults with type 2 diabetes and diabetic kidney disease. Can J Diabetes. 2019 ag.;43(6):415-20. doi: 10.1016/j.jcjd.2018.08.199

A/L B Vasanth Rao VR, Tan SH, Candasamy M, Bhattamisra SK. Diabetic nephropathy: An update on pathogenesis and drug development. Diabetes Metab Syndr Clin Res Rev. 2019 en.;13(1):754-62. doi: 10.1016/j.dsx.2018.11.054

Gu HF. Genetic and Epigenetic Studies in Diabetic Kidney Disease. Front Genet. 7 de junio de 2019;10:507. doi: 10.3389/fgene.2019.00507

Gembillo G, Cernaro V, Salvo A, Siligato R, Laudani A, Buemi M, et al. Role of Vitamin D Status in Diabetic Patients with Renal Disease. Medicina (Mex). 2019 jun. 13;55(6):273. doi: 10.3390/medicina55060273

Hu X, Liu W, Yan Y, Liu H, Huang Q, Xiao Y, et al. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism. Eur J Pharmacol. 2019 febr.;845:91-8. doi: 10.1016/j.ejphar.2018.09.037

Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020 jun.;16(6):317-36. doi: 10.1038/s41581-020-0256-y

Dong Z, Wang Y, Qiu Q, Zhang X, Zhang L, Wu J, et al. Clinical predictors differentiating non-diabetic renal diseases from diabetic nephropathy in a large population of type 2 diabetes patients. Diabetes Res Clin Pract. 2016 nov.;121:112-8. doi: 10.1016/j.diabres.2016.09.005

Balmer LA, Whiting R, Rudnicka C, Gallo LA, Jandeleit KA, Chow Y, et al. Genetic characterization of early renal changes in a novel mouse model of diabetic kidney

disease. Kidney Int. 2019 oct.;96(4):918-26. doi: 10.1016/j.kint.2019.04.031

Torres B, Itzaola O, de Luis D. Abordaje nutricional del paciente con diabetes mellitus e insuficiencia renal crónica: a propósito de un caso. Nutr Hosp. 2017;34(supl. 1):18-37. doi: 10.20960/nh.1237

Kowalski A, Krikorian A, Lerma EV. Diabetic Nephropathy for the Primary Care Provider: New Understandings on Early Detection and Treatment. Ochsner J. 2014;14(3):369-79.

Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, et al. Elevated levels of interleukin-18 and tumor necrosis factor-? in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Metabolism. 2003 my.;52(5):605-8. doi: 10.1053/meta.2003.50096

Hagnäs M, Sundqvist H, Jokelainen J, Tumminia A, Vinciguerra F, Loreto C, et al. The prevalence of chronic kidney disease and screening of renal function in type 2 diabetic patients in Finnish primary healthcare. Prim Care Diabetes. 2020 jun.;S175199182030190X. doi: 10.1016/j.pcd.2020.05.005

Fici F, Ari Bakir E, Ilkay Yüce E, Kanuncu S, Makel W, Tarim BA, et al. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease. High Blood Press Cardiovasc Prev. 2020 febr.;27(1):43-9. doi: 10.1007/s40292-020-00358-1

Oellgaard J, Gæde P, Persson F, Rossing P, Parving H-H, Pedersen O. Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. J Diabetes Complications. 2018 dic.;32(12):1133-40. doi: 10.1016/j.jdiacomp.2018.09.012

Perico N, Ruggenenti P, Remuzzi G. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. Curr Opin Pharmacol. abril de 2017;33:34-40. doi: 10.1016/j.coph.2017.03.006

Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Kidney and Transplant Group, editor. Cochrane Database Syst Rev [Internet]. 2012 dic. 12 [citado 2020 jun. 3]. doi: 10.1002/14651858.CD004136.pub3

Donaire JAG, Ruilope LM. Angiotensin receptor blockade in diabetic renal disease—Focus on candesartan. Diabetes Res Clin Pract. mayo de 2007;76(3):S22-30. doi: 10.1016/j.diabres.2007.01.017

Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. Am J Kidney Dis. 2018 jun.;71(6):884-95. doi: 10.1053/j.ajkd.2017.10.026

Kim Y, Park CW. New therapeutic agents in diabetic nephropathy. Korean J Intern Med. 2017 en. 1;32(1):11-25. doi: 10.3904/kjim.2016.174

Mima A. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complications. 2018 jul.;32(7):720-5. doi: 10.1016/j.jdiacomp.2018.04.011

Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019 nov.;7(11):845-54. doi: 10.1016/S2213-8587(19)30256-6

van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH. SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome. Clin J Am Soc Nephrol CJASN. 2017 abr. 3;12(4):700-10. doi: 10.2215/CJN.06080616

Liu X, Xu C, Xu L, Li X, Sun H, Xue M, et al. Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway. Metabolism. 2020 oct.;111:154334. doi: 10.1016/j.metabol.2020.154334

Association AD. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes - 2019. Diabetes Care. 2019 en. 1;42(supl. 1):S90-102. doi: 10.2337/dc19-S009

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017 ag. 31;377(9):839-48. doi: 10.1056/NEJMoa1616011

Tonneijck L, Muskiet MHA, Smits MM, Hoekstra T, Kramer MHH, Danser AHJ, et al. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. Diabetes Obes Metab. 2017;19(12):1669-80. doi: 10.1111/dom.12985

Novo Nordisk A/S. Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease [Internet]. clinicaltrials.gov; 2020 jun. [citado 2020 jun. 18]. Report No.: NCT03819153. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03819153

Wu C-H, Yang Y-W, Hung S-C, Kuo K-L, Wu K-D, Wu V-C, et al. Ketoanalogues supplementation decreases dialysis and mortality risk in patients with anemic advanced chronic kidney disease. Aguilera AI, editor. PLOS ONE. 2017 my. 5;12(5):e0176847. doi: 10.1371/journal.pone.0176847

Wang M, Xu H, Chong Lee Shin OL-S, Li L, Gao H, Zhao Z, et al. Compound ?-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways. J Transl Med. 2019 dic.;17(1):122. doi: 10.1186/s12967-019-1856-9

Ko G, Kalantar-Zadeh K, Goldstein-Fuchs J, Rhee C. Dietary Approaches in the Management of Diabetic Patients with Kidney Disease. Nutrients. 2017 jul 31;9(8):824. doi: 10.3390/nu9080824

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 jun. 13;380(24):2295-306. doi: 10.1056/NEJMoa1811744

Li X-F, Xu J, Liu L-J, Wang F, He S-L, Su Y, et al. Efficacy of low-protein diet in diabetic nephropathy: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2019 dic.;18(1):82. doi: 10.1186/s12944-019-1007-6

Nørgaard SA, Briand F, Sand FW, Galsgaard ED, Søndergaard H, Sørensen DB, et al. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin. Eur J Pharmacol. 2019 oct.;860:172537. doi: 10.1016/j.ejphar.2019.172537

Tauchi E, Hanai K, Babazono T. Effects of dietary protein intake on renal outcome and mortality in patients with advanced diabetic nephropathy. Clin Exp Nephrol. 2020 febr.;24(2):119-25. doi: 10.1007/s10157-019-01796-5

Suratkal LH, Khandekar A. The study of effect of ketoanalogues in delaying progression of chronic kidney disease in patients with diabetic nephropathy. Kidney Res Clin Pract. 2012 jun.;31(2):A95. doi: 10.1016/j.krcp.2012.04.634

enfermedad renal diabética
factores precipitantes
tratamiento
terapéutica nueva
diabetes